Introduction
Deregulated expression of c-Myc is observed in the majority of human cancers (Henriksson and Luscher, 1996; Nesbit et al., 1999) . c-Myc controls various aspects of cell behavior, including proliferation, differentiation, and apoptosis, by regulating, either activating or repressing, a considerable number of target genes (Oster et al., 2002) . To regulate the expression of target genes, c-Myc together with its heterodimerization partner Max recruits a number of different proteins that serve as cofactors (Grandori et al., 2000; Luscher, 2001; Oster et al., 2002) . The N-terminal transactivation domain of c-Myc interacts with TRRAP, a large protein that functions in complexes containing histone acetyltransferases (HATs) like GCN5 and TIP60 (McMahon et al., 2000; Park et al., 2001; Frank et al., 2003) . The coactivator CBP/p300 represents a third HAT that, however, binds to a C-terminal region of c-Myc (Vervoorts et al., 2003) . These HAT enzymes function at least in part by acetylating core histones, a mechanism that has been linked to chromatin opening and gene activation (Sterner and Berger, 2000; Strahl and Allis, 2000; Jenuwein and Allis, 2001) . In agreement, binding of Myc/Max heterodimers to E-box elements correlates with altered core histone acetylation at target promoters and increased transcription (Bouchard et al., 2001; Frank et al., 2001; Park et al., 2001; Xu et al., 2001; Nikiforov et al., 2002; Frank et al., 2003; Liu et al., 2003) . In addition to HATs, c-Myc has been reported to recruit an SWI/SNF complex that affects chromatin structure by remodeling nucleosomes (Cheng et al., 1999; Park et al., 2002) as well as a number of other proteins that may affect Myc-dependent transcription (Oster et al., 2002) . Together these findings provide evidence for diverse functions that can be targeted to promoters by Myc, indicating that Myc uses several mechanisms to modulate the expression of target genes. How and when these different functions are used by Myc to regulate genes is presently not understood in detail.
In an effort to identify novel c-Myc-interacting proteins, we copurified c-Myc with a novel poly(ADPribose) polymerase (PARP). This enzyme is a member of a growing family. By sequence comparison, a total of 18 potential PARP enzymes have been postulated (Ame et al., 2004) , our identified protein is identical to PARP-10. The best studied PARP enzyme is PARP-1 (D' Amours et al., 1999) . It appears to confer the majority of NAD þ -dependent PARP activity in cells. PARP-1 is activated in response to DNA damage and plays an important role in DNA repair processes, apoptosis, and cell cycle control (D'Amours et al., 1999; Burkle, 2001; Smith, 2001; Tong et al., 2001; Bouchard et al., 2003) . PARP-2, PARP-3, Tankyrase-1 and -2, and VPARP are additional PARP enzymes that have been identified in recent years. PARP-2 is also activated in response to DNA damage (Ame et al., 1999; Schreiber et al., 2002) . The loss of either PARP-1 or PARP-2 in mice results in increased sensitivity to ionizing radiation, nevertheless these animals are viable. In contrast, loss of both enzymes is embryonically lethal, suggesting an essential function of these enzymes during early mouse development Wang et al., 1997; Masutani et al., 2000; Menissier de Murcia et al., 2003) . Tankyrase-1 and -2 are involved in telomere maintenance and possess additional poorly defined functions in the cytoplasm (Smith et al., 1998; Chi and Lodish, 2000; Smith and de Lange, 2000; Lyons et al., 2001; Cook et al., 2002; Sbodio et al., 2002) . VPARP is a major component of vaults, cytoplasmic ribonucleoprotein particles of unknown function (Kickhoefer et al., 1999) . A recent addition to the PARP family is PARP-3 that is localized to the centrosome and appears to modulate cell cycle progression (Augustin et al., 2003) .
In recent years, a number of publications have brought to light an involvement of ADP-ribosylation in the control of gene transcription (Kraus and Lis, 2003) . This was initially suggested by the observation that histones are modified by ADP-ribose and that this modification affects chromatin organization. In addition, the interaction of PARP-1 with several transcriptional regulators suggests that PARP-1 functions also as a cofactor of transcription, in some instances independent of its PARP activity (D'Amours et al., 1999; Hassa and Hottiger, 2002; Kraus and Lis, 2003) . Together these findings led to the suggestion that ADP-ribosylation represents an additional posttranslational mechanism used in cells to regulate gene transcription. Our study identifies and characterizes a novel PARP enzyme, PARP-10, that can associate with the oncoprotein c-Myc. PARP-10 possesses PARP activity and shuttles between the nuclear and cytoplasmic compartments. In addition, PARP-10 inhibits transformation of primary cells. We speculate that PARP-10 has a role in nuclear processes that might include the regulation of chromatin and gene transcription and nuclear/cytoplasmic transport.
Results

Identification of novel Myc-associated proteins
In an effort to identify novel c-Myc-interacting proteins, Jurkat T cells were lysed in F-buffer and Myc-containing complexes were immunopurified. Myc/Max complexes isolated from F-buffer extracts are capable to bind to DNA and the interaction with the coactivators CBP/p300 is preserved (Sommer et al., 1998; Vervoorts et al., 2003) . The monoclonal antibody (mAb) 6A10, which recognizes an N-terminal epitope in c-Myc (Sommer et al., 1998) , and the Mad1-specific mAb 5C9 for control (Sommer et al., 1997) were covalently linked to Affi-gel 10 and used for immunopurifications. From experiments with lysates of either 35 S-methioninelabeled or -unlabeled cells combined with autoradiography, silver staining, or Western blotting, evidence was obtained for several Myc-associated proteins. Three proteins with apparent molecular weights of 86, 110, and 150 kDa were identified reproducibly ( Figure 1a ). In addition, the known c-Myc interaction partners Max, YY1, and CBP/p300 were specifically copurified (data not shown).
The three protein bands were excised from the gel, eluted, and trypsinized. Following separation and purification by HPLC, the tryptic peptides were subjected to Edman degradation. Eight peptides were sequenced from the material obtained from the 150 kDa species (indicated in Figure 1b ) and the sequences were used to screen data bases. We identified several EST clones and assembled a cDNA of roughly 3550 bps. The cDNA included potential polyadenylation sites at the 3 0 end (data not shown) and an open reading frame (ORF) with the capacity to encode a protein of 1025 amino acids (aa) (Figure 1b ). The first AUG was preceded by an in frame STOP codon (data not shown). All eight peptides originally identified were contained within the ORF (Figure 1b ). This p150 protein is identical to PARP-10 (Ame et al., 2004) . The sequencing of several peptides of p110 revealed that it is identical to nucleolin (data not shown). The characterization of p86 will be described elsewhere.
Domains in PARP-10
Homology searches identified several regions of potential functional relevance (Figure 1b) . Near the N-terminus, a region with homology to RNA recognition motifs (RRM, aa 11-85) was identified. Similar domains in other proteins mediate binding to RNA and ssDNA (Crowder et al., 1999; Conte et al., 2000; Dallaire et al., 2000; Fiset and Chabot, 2001; Ginisty et al., 2001) . Further C-terminal, a Gly-rich domain is found (aa 281-399). Such domains in combination with RRM motifs have been implicated in RNA binding, most notably in nucleolin (Ginisty et al., 2001) , which also was present in our purification. It remains to be determined whether the RRM and Gly-rich domains of PARP-10 function in binding to nucleic acids. The Cterminal half of PARP-10 contains two overlapping domains, a Glu-rich region from aa 588-697 and a region with homology to catalytic domains of PARP enzymes (aa 632-1013). In addition, two ubiquitininteracting motifs (UIM, are localized in the C-terminal half (Polo et al., 2003) . Thus, PARP-10 is built of a unique set of structural elements that have not been found previously in a similar configuration.
Northern blot analysis using a fragment of the cDNA revealed a single 3.8 kb mRNA species in Jurkat T cells (Figure 1c, left panel) . To test whether the ORF can encode a protein with the appropriate size, the cDNA was in vitro transcribed/translated and analysed by SDS-PAGE. We observed a protein with the expected size of 150 kDa (Figure 1c, right panel) . Together, these findings strongly suggest that we have cloned a cDNA that encodes the entire reading frame of PARP-10.
PARP-10 binds to two domains within c-Myc
The interaction between c-Myc and PARP-10 was verified in coimmunoprecipitation experiments using tagged versions of the two proteins transiently expressed in COS7 cells. HA-PARP-10 and Flag-c-Myc were coimmunoprecipitated with antibodies to either tag only when both proteins were expressed simultaneously ( Figure 1d ). To analyse further the interaction of PARP-10 with c-Myc, we performed GST pull down experiments. Specific binding of c-Myc to GST-PARP-10(519-1021), GST-PARP-10(588-1021), GST-PARP-10(700-1021), and GST-PARP-10(1-907) was observed ( Figure 1e and data not shown), suggesting that Myc binds to a region encompassing aa 700-907 within the C-terminal half of PARP-10. PARP-10 interacted with at least two domains of c-Myc, one in the N-terminal 156 amino acids requiring Myc Box II (MBII), the other in the C-terminal 176 amino acids (Figure 1f ). Both these regions are important for the ability of Myc to transform cells (Henriksson and Luscher, 1996) .
Chromosomal localization and expression pattern of PARP-10
The chromosomal localization of the PARP-10 gene was determined by fluorescence in situ hybridization (FISH) to the tip of the long arm of chromosome 8 (8q24) (Figure 2a ). Since the c-myc gene is also localized to 8q24, we defined the relative position of the two genes in Burkitt's lymphoma cell lines that contain mapped translocations involving the c-myc gene (Boxer and Dang, 2001) . In all three cell lines analysed, that is, CA46, Raji, and Manca, the PARP-10 gene was translocated to chromosome 14 or respective translocation partners ( Figure 2b and data not shown). This demonstrates that PARP-10 is localized telomeric of cmyc, a position confirmed and specified to 8q24.3 recently by a published extension of the human genome project.
The tissue expression pattern of PARP-10 was studied by Northern blot analysis. The 3.8 kb mRNA was detected in all human tissues analysed, albeit at distinct levels ( Figure 2c ). In comparison to the actin signal that served as control, low-level expression was obvious in heart, brain, placenta, lung, skeletal muscle, and colon. Intermediate levels of expression were observed in liver, kidney, pancreas, prostate, testis, ovary, intestine, and leukocytes, while high-level expression was evident in spleen and thymus. This identifies PARP-10 as a ubiquitously expressed gene with some preference for hematopoietic tissues.
The C-terminal domain of PARP-10 possesses PARP activity
The initial data base search revealed that the C-terminal half of PARP-10 has limited homology to the catalytic domain of PARP-1. The PARP domain of human PARP-10 was compared with the corresponding domain of human and chicken PARP-1. Of the 382 aa of the PARP-10-PARP domain, 34 are identical (8.9%) with the PARP domain of ck-and hu-PARP-1 (Figure 3a) . To assess whether PARP-10 possesses PARP activity, the putative PARP domain was expressed as GST fusion protein (GST-PARP-10(519-1021)). It was expressed inefficiently and a number of breakdown products were observed ( Figure 3b ). When incubated with 32 P-NAD þ , one prominently labeled protein species was observed that corresponded to the largest GST fusion protein ( Figure 3b ). None of the smaller proteins was labeled to any significant extent, suggesting that these fragments have lost an essential portion of the PARP domain or cannot be modified by ADP-ribosylation or both. Together, this demonstrates enzymatic activity of the PARP domain of PARP-10.
To test for polymerase activity, we performed PARP assays in the presence of increasing amounts of unlabeled NAD þ with a constant amount of 32 P-NAD þ . We observed an increase in apparent molecular weight of about 20 kDa of 32 P-labeled GST-PARP-10(519-1021) (Figure 3c ), indicative of the formation of ADPribose oligomers or polymers. These experiments were corroborated by using the mAb 10H that is specific for poly(ADP-ribose) (PAR) and does not recognize monomers or oligomers (Kawamitsu et al., 1984) . As above, GST-PARP-10(519-1021) was incubated with 32 P-NAD þ in the presence of increasing amounts of unlabeled NAD þ . Parallel aliquots of the reactions were immunoprecipitated with antibodies specific either for PAR (mAb 10H) or for PARP-10 (890-6, see below for characterization) or with the corresponding preimmunserum (890 pi). With increasing amounts of unlabeled NAD þ , more labeled PARP-10 was immunoprecipitated with anti-PAR relative to anti-PARP-10 ( Figure 3d ). Together, these findings support the notion that PARP-10 possesses auto-PARP activity.
To substantiate the low degree of identity (Figure 3a ), the relatedness of human PARP-10 with the PARP domain of ck-PARP-1 was analysed by fold recognition algorithms. We observed that the human PARP-10 sequence is compatible with the architecture of a PARP domain and the three-dimensional structure of the catalytic domain of PARP-10 was modeled according to this alignment using the coordinates of ck-PARP-1 as template (Ruf et al., 1996) (Figure 3e ). Several amino acids in the active center are conserved. Two of these, His887 and Gly888 (Figure 3a , black arrowheads and (Figure 3f) . A previous study identified Lys893 in hu-PARP-1 as important for catalytic activity (Simonin et al., 1990) . In addition, this amino acid could be crosslinked to a modified NAD þ (Kim et al., 1997) . Although the corresponding Lys916 in PARP-10 is not part of the active center, its mutation resulted in a strong reduction of catalytic activity (Figure 3a , green arrow head, and Figure 3f ). Together these functional studies support our structural model.
Core histones are substrates of the PARP domain of PARP-10
The data described above define that PARP-10 automodifies. To identify additional substrates, we tested whether c-Myc, Max, YY1, histone H1, or core histones are poly(ADP-ribosyl)ated by GST-PARP-10(519-1021) or GST-PARP-10(588-1021). YY1, histone H1, and core histones have been shown previously to be poly(ADP-ribosyl)ated by PARP-1 (D' Amours et al., 1999; Oei and Shi, 2001) . While c-Myc, Max, histone H1, and YY1 were not poly(ADP-ribosyl)ated in vitro (Figure 4a and data not shown), all four core histone were substrates with a preference for histone H2A (Figure 4b) , suggesting a potential role of PARP-10 in the regulation of chromatin.
Analysis of full-length PARP-10
To address whether full-length PARP-10 functions as a PARP, an HA-tagged version of PARP-10 was expressed transiently in COS7 cells (Figure 5a ), immunoprecipitated with antibodies specific for the HA-tag and tested for PARP activity (Figure 5b) . A single 150 kDa 32 P-labeled protein species was observed. In immunoprecipitations of lysates from control-transfected cells or from cells expressing HA-PARP-10(1-907), deleting part of the PARP domain, no PARP activity could be detected (Figure 5a and b) . In addition, HA-PARP-10(G888W) did not reveal any PARP activity (Figure 5c ), as expected from the analysis of the corresponding mutant in GST-PARP-10(519-1019) (Figure 3f ).
In order to study endogenous PARP-10, we generated two different rabbit antisera (animals 890 and 891) against GST-PARP-10(1-907). The immunsera, but not the corresponding preimmunsera, recognized HA-PARP-10 overexpressed in COS7 cells and endogenous PARP-10 from Jurkat cells (Figure 5a ). Furthermore, both sera were capable of immunoprecipitating PARP PARP-10, a novel poly(ADP-ribose) polymerase M Yu et al activity associated with overexpressed as well as endogenous PARP-10 while the corresponding preimmunsera were inactive (Figure 5b ). Together, these findings demonstrate that full-length PARP-10 possesses PARP activity.
Differential expression and subcellular distribution of PARP-10
PARP-10 is ubiquitously expressed (Figure 2c ). To determine the expression of the protein, we performed Western blot analyses of whole-cell extracts of several human tumor cell lines. We observed that in hematopoietic lines (the T-cell line Jurkat, the promyelocytic lines HL60 and U937, and the Burkitt's lymphoma lines Manca, Namalwa, CA46, Ramos), significant levels of PARP-10 were detected. In addition, high expression was seen in the breast carcinoma line T47D, while in another breast cancer line, MCF7, and in the osteosarcoma line SAOS and in the human embryonic kidneyderived line HEK293, little expression was measured (Figure 6a ). For the determination of the subcellular localization of PARP-10, we generated mAbs. Six of these recognized HA-PARP-10 overexpressed in COS7 cells by Western blot analysis (Figure 6b ). Three of these mAbs were also able to immunoprecipitate endogenous PARP-10 under stringent conditions (Figure 6c ) and recognized overexpressed PARP-10 by indirect immunofluorescence analysis (Figure 6d and data not shown). Overexpressed PARP-10 in U2OS osteosarcoma cells was predominantly localized in the cytoplasm (Figure 6d, top panel) . This is consistent with the lack of an obvious nuclear localization signal (NLS). However in the presence of leptomycin B (LMB), overexpressed PARP-10 accumulated efficiently in the nuclear compartment (Figure 6d ), indicating that PARP-10 when transported to the nucleus is efficiently exported probably by a Crm1-dependent mechanism (Fornerod et al., 1997; Fukuda et al., 1997) . No staining was detected under these conditions in untransfected cells. Endogenous PARP-10 was stained in T47D cells (Figure 6e) . In untreated cells, both cytoplasmic and nuclear staining was observed, whereas after LMB treatment PARP-10 was preferentially localized in the (Figure 6e , lower panels). The predominant cytoplasmic localization of PARP-10 was corroborated by fractionation experiments (data not shown). To address the role of the potential Leu-rich NES, this sequence was mutated by replacing three Leucine residues by Alanines (Figure 6f) . The resulting protein, HA-PARP-10DNES, was predominantly localized to the nucleus (Figure 6g ). These findings suggest that PARP-10 shuttles between the cytoplasmic and the nuclear compartments.
PARP-10 inhibits cell proliferation
The ability of PARP-10 to regulate cell proliferation and transformation was analysed in rat embryo fibroblasts (REF) cotransformation assays. Transformation by cMyc/Ha-Ras was inhibited by coexpressing PARP-10, PARP-10(1-907), or PARP-10(G888W) in a dosedependent manner (Figure 7a and b) . In contrast, mutants that are predominantly localized in the nucleus and are probably unable to shuttle (PARP-10DNES and PARP-10DNES-G888W) did not inhibit transformation ( Figure 7b ). All mutants were expressed equally (data not shown). The inhibition of E1A/Ha-Ras-dependent transformation was even more pronounced, again independent of PARP activity (Figure 7c ). Furthermore, PARP-10DNES-G888W showed little inhibitory activity ( Figure 7c ). These findings were expanded by testing whether PARP-10 was capable to interfere with proliferation in 3T3-L1 mouse fibroblasts. These cells were serum starved prior to microinjection of PARP-10-expressing plasmids. The injected cells were then scored for progression into S phase in response to addition of serum. We observed that PARP-10 and PARP-10(1-907) efficiently inhibited entry into S phase (Figure 7d ). To address whether these effects are due to a general inhibition of cell growth, we generated HEK293 cell lines with inducible expression of PARP-10 and the different mutants described above. No significant inhibition of proliferation was observed (M Yu and B Lu¨scher, unpublished observations). In addition, we performed colony formation assays in HEK293 and in In neither cell type we observed any growth inhibitory effect (data not shown). Thus, PARP-10 is a potent inhibitor of transformation of primary REFs and of immortalized fibroblasts but not a general growth inhibitory protein.
Discussion
Here we describe a protein with an apparent molecular weight of 150 kDa as a novel c-Myc interaction partner that is dubbed PARP-10 ( Figure 1 ). We detected homology of the C-terminal region of PARP-10 to PARP domains. This homology was rather poor at the amino-acid level. However, three-dimensional modeling revealed that the C-terminal region of PARP-10 folded into a domain similar to the PARP domain of ck-PARP-1 (Ruf et al., 1996) (Figure 3) . Together with the demonstration that PARP-10 has PARP activity, this protein represents a previously unknown member of poly(ADP-ribose) polymerases. Several PARP enzymes with diverse functions have been identified in recent years as summarized in the Introduction. Furthermore, it has been reported that at least 18 proteins with a PARP domain exist in mammals (Ame et al., 2004) . This indicates that post-translational modifications of proteins by PAR are most likely widespread and associated with diverse functions. Our biochemical evidence identifies PARP-10 as an enzyme that ADP-ribosylates itself and core histones (Figures 3-5) . Neither c-Myc nor Max is modified by PARP-10 in vitro. The majority of described poly(ADPribosyl)ated proteins are nuclear (D'Amours et al., 1999) . Many of these proteins are thought to be modified by PARP-1; however, other PARP enzymes have not been studied in great detail. These PARP substrates include proteins involved in DNA repair and other nuclear processes such as DNA synthesis and gene transcription. In particular, the modification of histones by PAR has been suggested to affect chromatin structure and gene expression (D'Amours et al., 1999; Kraus and Lis, 2003) . Thus, it will be important in the future to define the role of PARP-10 in the regulation of chromatin and to determine the functional relevance.
A large number of proteins have been identified that interact with the transcriptional regulator c-Myc. At least some of these, including TRRAP with its associated HAT activities, an SWI/SNF-related complex, and CBP/p300, are thought to mediate the Furthermore, so far we did not observe effects of PARP-10 on the expression of the cyclin D2 gene, an established c-Myc target (Bouchard et al., 2001 ) (data not shown). Additional reasons that complicate the analysis of PAR modifications include the lack of efficient reagents to specifically detect poly(ADP-ribosyl)ated proteins in cells and the very short half-life of the polymers. The latter may be as short as 1 min, probably due to the prevalent activity of poly(ADPribose) glycohydrolase (PARG). Mono-and oligo(ADP-ribose) are more stable and may persist with a half-life of several hours (D'Amours et al., 1999; Kraus and Lis, 2003) . These findings suggest that ADPribosylation can function in short-term regulation of substrates. The consequences of such modifications may affect, comparable to other modifications, protein structure, DNA binding, protein-protein interactions, and/or chromatin structure. A substantial body of evidence points to a role of PARP-1 in gene transcription. PARP-1 directly interacts with and/or ADP-ribosylates several transcription factors. Interaction has been shown, among others, with NF-kB, p53, B-Myb, and nuclear receptors (Hassa and Hottiger, 2002; Kraus and Lis, 2003) . In these situations, PARP-1 can function as cofactor that either enhances or represses transcription dependent on the specific enhancer/promoter context. Furthermore, PARP-1 poly(ADP-ribosyl)ates several transcription factors, including p53 and YY1, thereby affecting their functions. Alternatively, PARP-1 may bind directly to certain DNA structures or specific sequences (Hassa and Hottiger, 2002; Kraus and Lis, 2003) . It is important to note that regulation of gene expression by PARP-1 requires catalytic activity in some but not all situations. Therefore, PARP-1 may not only function by poly (ADP-ribosyl)ating chromatin-associated proteins but also by mediating protein-protein interactions (D'Amours et al., 1999; Kraus and Lis, 2003) .
Further support for a role of PARP-1 in the control of gene transcription and chromatin structure comes from recent studies in Drosophila melanogaster. While in mammals the PARP family is rather large, only two PARP enzymes, a PARP-1 and a tankyrase-1 ortholog, have been reported in Drosophila (Tulin et al., 2002) . In agreement, PARP-10 orthologs could be identified neither in Drosophila nor in Caenorhabditis elegans (data not shown). In Drosophila, PARP-1 is required for chromatin organization and is associated with areas of high transcriptional activity and decondensed chromatin (chromosomal puffs) (Tulin et al., 2002; Tulin and Spradling, 2003) . Gene activation in response to stress and steroid hormones results in an increase in poly (ADP-ribosyl)ated proteins at the responsive loci, which is required to obtain normal-sized puffs and efficient gene expression. Together these findings define an important role of PARP-1 and for PAR modification in gene transcription.
Expression of PARP-10 in primary cells inhibits Myc/ Ha-Ras-and E1a/Ha-Ras-dependent transformation (Figure 7) . Furthermore, PARP-10 interferes with Sphase progression in immortalized cells (Figure 7 ). This indicates that PARP-10 is a regulator of cell behavior. However, it is not a general inhibitor of proliferation since expression of PARP-10 in tumor-derived cell lines did not inhibit cell growth (unpublished observation). This activity of PARP-10 was independent of a functional PARP domain, suggesting that other domains within PARP-10 are required for this activity. Interestingly mutants that were not efficiently exported from the nucleus due to mutations in the NES were unable to inhibit transformation. This suggests that PARP-10 has an important function in transport processes. In this respect the RRM and Gly-rich domain might be relevant. RRM domains often mediate the specific recognition of RNA important for a number of cellular processes, including nucleo-cytoplasmic transport, splicing, and protein biosynthesis (Dreyfuss et al., 1996; Nakielny and Dreyfuss, 1999) . The RRM of PARP-10 is highly homologous to the known RRMs of nucleolin, hnRNP A1, sex lethal, and PTB (data not shown) (Crowder et al., 1999; Conte et al., 2000; Dallaire et al., 2000; Fiset and Chabot, 2001; Ginisty et al., 2001) . In addition, RRMs have also been indicated in the binding of single-stranded DNA relevant for telomere maintenance (Crowder et al., 1999; Dallaire et al., 2000; Fiset and Chabot, 2001) . These homologies indicate a potential role for PARP-10 as an RNA and/or ssDNA-binding protein. Thus, the lack of inhibition of transformation by the DNES mutants, the potential function in RNA binding, and the recent suggestion for a role of c-Myc in the control of rRNA gene transcription (Poortinga et al., 2004 ) may hint at a role of PARP-10 together with c-Myc in RNA processing.
PARP-10 does not contain an obvious NLS. Nevertheless upon treatment with LMB, an inhibitor of Leurich NES-mediated nuclear export (Fornerod et al., 1997; Fukuda et al., 1997) , PARP-10 accumulates in the nucleus and mutation of the NES results in a mutant that resides predominatly in the nucleus (Figure 6 ). Presently, it is not clear what mediates nuclear uptake of PARP-10. We have tested whether stress signals, including DNA damage, or coexpression of Myc increases the portion of PARP-10 localized in the nucleus. However, no strong enhancement was observed (data not shown), which may indicate that the export of PARP-10 is too rapid or that these are inappropriate signals. Our findings suggest that PARP-10 shuttles between the cytoplasmic and the nuclear compartments. Such proteins are involved in regulating many aspects of cell physiology, including transport of RNA, aspects of cell cycle control, and transcription (Mattaj and Englmeier, 1998; Michael, 2000; Macara, 2001) . In this respect, the presence of two UIM sequence elements is interesting, since these have, among others, been found in proteins that are involved in nuclear import and export (Polo et al., 2003) .
PARP-10 is localized on chromosome 8q24.3. Although this chromosomal location is implicated in several different human cancers, no detailed information is available that would suggest a role of PARP-10 in specific tumors. Of note is the finding that the expression level of PARP-10 varies greatly in different cell lines (Figure 6a) . Together with the ability of PARP-10 to inhibit transformation of REFs, an involvement of this protein in tumorigenesis is possible and will be addressed in the future.
Material and methods
Cells, transient transfections, and transformation assays
Hematopoietic cell lines were maintained in RPMI 1640, all other lines in Dulbecco's modified Eagle's medium. The supplements were 100 U of penicillin, 100 mg/ml streptomycin, and 10% fetal calf serum (FCS). Transient transfection assays were performed as described before (Luscher-Firzlaff et al., 1999) . Transformation assays using rat embryo cells were carried out essentially as described previously (Cerni et al., 1995) . Microinjection of 3T3-L1 mouse fibroblasts was performed as described before (Sommer et al., 1997) .
Purification and identification of c-Myc-associated proteins
Jurkat T cells were grown to mid log-phase and lysed at 10 7 cells/ml in F-buffer (10 mM Tris-HCl, pH 7.05, 50 mM NaCl, 30 mM Na 4 P 2 O 7 , 50 mM NaF, 5 mM ZnCl 2 , 100 mM Na 3 VO 4 , 1% Triton X-100, 1 mM PMSF, 5 U/ml a2-macroglobulin, 2.5 U/ml pepstatin A, 2.5 U/ml leupeptin, 0.15 mM benzamidin) containing 10% glycerol (Sommer et al., 1998) . Lysates were clarified by high-speed centrifugation. In all, 5 mg each of mAb 6A10 (recognizing an N-terminal epitope in c-Myc; Sommer et al., 1998) , and the Mad1-specific mAb 5C9 for control (Sommer et al., 1997) were covalently linked to 1.2 ml of Affi-Gel 10 (Bio-Rad) according to the manufacturer's instructions and used for immunopurifications. F-buffer lysate (50 ml) was applied to each affinity matrix. Beads were washed with 20 bed volumes of F-buffer/10% glycerol. Bound proteins were eluted with Laemmli gel-loading buffer and separated by SDS-PAGE.
Coomassie blue-stained bands were excised from the gel, washed in 0.5 M Tris/acetonitrile (1 : 1, v/v) and dried. The proteins were reduced and alkylated prior to digestion with 0.1 mg trypsin in 0.05 M Tris-HCl, pH 8.5, 10% acetonitrile, 1 mM CaCl 2 at 371C overnight. The resulting peptides were extracted from the gel in 2% trifluoroacetic acid at 601C for 1 h and separated by RP-HPLC on a mRPC C2/C18 SC2.1/10 column using the SMART system. Peptides were eluted with a gradient of 0.5%/min buffer B (0.1% trifluoroacetic acid, CH 3 CN) in buffer A (0.1% trifluoroacetic acid, H 2 O) at a flow rate of 100 ml/min. Selected peptides were sequenced on a Procise Proteint sequencer (Applied Biosystems Inc.).
Plasmids
The sequence information from the p150 peptides was used to identify and assemble a human PARP-10 cDNA. The peptides were contained within the EST clone AL040630 and AA909139 (RZPD, Berlin). The latter contained a poly(A) sequence at its 3 0 end. The full-length cDNA encodes a protein of 1025 amino acids and was cloned into pEV-HA-RF0 (Matthias et al., 1989) to obtain pEV-HA-PARP-10. Subsequently, the full-length sequence was published by NCBI (AK027370). The plasmids encoding various fragments of PARP-10 fused to GST and PARP-10 mutants were obtained by standard cloning techniques. All clones were verified by sequencing. pcDNA3-Flag-Myc was obtained from M Eilers, plasmids expressing GST-Myc-N262 and GST-Myc-C176 were a gift from R Eisenman. Bacterial expression vectors for maltose-binding protein (MBP), pMBP-Pre, and for MBPMyc, pMBP-Pre-Myc, were provided by H Ariga.
FISH
For c-myc, the commercially available Digoxigenin-labeled cmyc probe (Qbiogene; cat. no. P5117-DG.5) was used according to the manufacturer's recommendations. For PARP-10, EST clone 465560 was used as probe and Digoxigenin labeled using standard nick translation procedures. Burkitt's lymphoma cell lines and peripheral blood lymphocytes (PBL) were arrested in mitosis by colchicin. In total, 100-200 ng of labeled PARP-10 DNA probe was hybridized together with 500 ng of human cot-1-DNA (Life Technologies Inc., Gaithersburg, MD, USA) and 10 mg of sonicated salmon sperm DNA in a hybridization mixture consisting of 55% formamide, 1 Â SSC, and 10% dextrane sulfate (pH 7.0). FISH, posthybridization washing steps, and digoxigenin detection procedures were carried out as described elsewhere (Lichter et al., 1990) . Microscopical evaluation was performed using an Olympus epifluorescence microscope; digital images were acquired by CCD-camera employing the Metasystems ISIS software.
Northern blotting
The multitissue Northern blots were obtained from Clontech. RNA of logarithmically growing Jurkat cells was extracted with the RNeasy total RNA kit (Qiagen). RNA (15 mg) was separated on 1% formaldehyde-agarose gels. The RNA was blotted onto GeneScreent membrane and hybridized with 32 Plabelled AA465560 in 0.25 M NaP i , 7% SDS, 1 mM EDTA at 651C. The membrane was washed with 50 mM NaP i , 0.5% SDS.
Protein analyses, antibodies and in vitro transcription and translation
For in vivo interaction assays, whole-cell lysates were prepared in F-buffer. Coimmunoprecipitated proteins were detected by Western blot analysis. PARP-10 expression was analysed by Western blotting using whole-cell extracts prepared in RIPA buffer (Luscher-Firzlaff et al., 1999) . For immunoprecipitations and Western blot analysis, anti-HA-tag mAb 3F10 (Roche) and anti-Flag-tag mAb M2 (Sigma) were used. mAb 10H specific for PAR was kindly provided by S Oei. Polyclonal antisera and mAbs against PARP-10 were generated by immunizing New Zealand white rabbits and LOU/C rats, respectively, with a bacterially expressed GST-PARP-10(1-907) fusion protein. GST-pulldown assays were performed as described previously (Luscher-Firzlaff et al., 1999) . PARP-10 and c-Myc were in vitro transcribed and translated using the TNT-coupled reticulocyte lysate system (Promega).
PARP assays
Bacterial expressed GST-PARP-10 fusion protein (1 mg) was incubated in 50 mM Tris-HCl, pH 8.0, 0.2 mM DTT, 4 mM MgCl 2 with 1 mCi 32 P-NAD at 301C for 30 min. Substrates were added in the range of 1-2 mg. The reactions were stopped by adding SDS-sample buffer and heating at 951C for 5 min.
Sequence analysis and molecular modeling
Homology and domain searches have been performed using BLAST. The ProCeryon program package was used as the main prediction tool for molecular modeling (ProHit package ProCeryon Biosciences GmbH, Salzburg, Austria). It uses knowledge-based potentials for atom pair and protein solvent interactions that were derived from a database of known structures (Domingues et al., 1999) . The resulting models were evaluated using different ProSA II (King's Beech Biosoftware) type z-scores based on pair interactions and surface terms. Models are generated for all chains in a fold library and ranked by the corresponding z-scores (Sippl, 1993) . The X-ray structure of the ch-PARP domain (pdb accession code: 1pax) served as a template for the three-dimensional model of the catalytic domain of PARP-10 ( Ruf et al., 1996) . Based on the alignment generated by the fold recognition procedure, aminoacid residues were exchanged in the template. Insertions and deletions in the PARP-10 PARP domain were modeled by using a database approach included in the software package WHATIF (Vriend, 1990) . The database was searched for a peptide sequence of the appropriate length, which was fitted to the template. All loops were selected from the database so as to give a minimum root means square distance between the ends of the loops. In a last step, the three-dimensional structural models were energy-minimized, using the steepest descent algorithm implemented in the GROMOS force (van Gunsteren et al., 1996) . For graphical representation, the Ribbons program (Carson, 1991) was used.
Immunofluorescence
Cells were grown on coverslips, rinsed in PBS and fixed in 4% paraformaldhyde (in PBS) at room temperature for 30 min. Then the samples were washed three times in PBS, incubated in 0.2% Triton X-100/PBS at room temperature for 10 min and rinsed again in PBS. Samples were incubated with primary antibody (1 : 200 and 1 : 50 dilution of 5H11 for overexpressed and endogenous PARP-10, respectively) in PBS containing 20% horse serum at 371C for 60 min. After washing in PBS, samples were incubated with secondary antibody (1 : 300 dilution of Cy 3 -coupled anti-rat antibodies) at 371C for 45 min. The DNA was stained with Hoechst 33258 (0.2 mg/ml in PBS with 20% horse serum) at room temperature for 5 min. Samples were embedded in Mowiol 488 and dried at room temperature overnight.
